• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

29.96 -0.92 (-2.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,874,375
Open 30.75
Bid (Size) 28.82 (200)
Ask (Size) 32.40 (100)
Prev. Close 30.88
Today's Range 29.88 - 30.86
52wk Range 10.59 - 32.79
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Roivant (ROIV) Q4 2025 Earnings Transcript ↗
May 20, 2026
Roivant (ROIV) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Roivant Sciences Q4 Earnings Call Highlights ↗
May 20, 2026
Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary... 
Via MarketBeat
Topics Earnings Government

Performance

YTD
+36.6%
+36.6%
1 Month
+2.8%
+2.8%
3 Month
+10.3%
+10.3%
6 Month
+48.2%
+48.2%
1 Year
+173.9%
+173.9%

More News

Read More
Stay updated with the stocks that are on the move in today's pre-market session. ↗
May 20, 2026
Via Chartmill
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗
May 14, 2026
Via Chartmill
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
May 16, 2026
Via The Motley Fool
News headline image
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
April 02, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 02, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
April 02, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
March 15, 2026
Via The Motley Fool
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
March 05, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗
March 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
March 04, 2026
Via Stocktwits
Topics Intellectual Property
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
March 03, 2026
Via Stocktwits
Topics Intellectual Property
News headline image
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 03, 2026
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
March 03, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
March 03, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
February 22, 2026
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗
February 13, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 29.96
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 05/22/26 04:00 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 20.73B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 21B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap